

State of Oklahoma SoonerCare

Hyftor™ (Sirolimus topical gel) Prior Authorization Form

Member Name:	Date of Birth	: Member ID#:	_
Drug Information			
Pharmacy Billing (NDC:) Start [Date (or date of next dose):	_
Dose:	Regime	en:	_
Billing Provider Information			
Pharmacy NPI:	Pharma	acy Name:	
Pharmacy Phone:	Pharma	acy Fax:	
Prescriber Information			
Prescriber NPI:	Prescriber Nam	me:	_
Prescriber Phone:	Prescriber Fax:	Specialty:	_
	Criter	ria	
For Initial Authorization: (Initial app	rovals will be for a c	duration of 12 weeks)	
Does member have a documented complex (TSC)? Yes No		l angiofibromas associated with tuberous sclerosis	}
Does member have facial angiofib Yes No	promas that are at le	east 2mm in diameter with redness in each?	
	of age, are medical i	issues caused by facial angiofibromas?	
Yes No a. If yes, please provide specific documentation of clinically significant medical issues. (Hyftor™ is not covered for cosmetic use.)			
			_
Additional Information:			_
For Continued Authorization:			_
 Is the member responding well to Anticipated duration of treatment: 	treatment? Yes	No	
Additional Information:			_
Prescriber Signature:	tio modically no	Date: Date:essary and all information is true and correct to	
the best of my knowledge. Failure to chart notes. Specific information will be req	complete this form in t	full will result in processing delays. Please do not send in	U

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm – 231 3/2/2023